S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
JP Morgan analyst: Oil to hit $380 per barrel (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Biden To Unleash "Choke Point" Operation On America? (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Biden To Unleash "Choke Point" Operation On America? (Ad)
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
JP Morgan analyst: Oil to hit $380 per barrel (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Biden To Unleash "Choke Point" Operation On America? (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Biden To Unleash "Choke Point" Operation On America? (Ad)
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
JP Morgan analyst: Oil to hit $380 per barrel (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Biden To Unleash "Choke Point" Operation On America? (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Biden To Unleash "Choke Point" Operation On America? (Ad)
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
JP Morgan analyst: Oil to hit $380 per barrel (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Biden To Unleash "Choke Point" Operation On America? (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Biden To Unleash "Choke Point" Operation On America? (Ad)
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
NASDAQ:KURA

Kura Oncology - KURA Stock Forecast, Price & News

$12.23
+0.37 (+3.12%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$11.85
$12.25
50-Day Range
$10.71
$14.60
52-Week Range
$10.30
$19.93
Volume
432,314 shs
Average Volume
637,775 shs
Market Capitalization
$837.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.20

Kura Oncology MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
155.1% Upside
$31.20 Price Target
Short Interest
Bearish
11.00% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.76
Upright™ Environmental Score
News Sentiment
0.30mentions of Kura Oncology in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$73,270 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.38) to ($2.24) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

704th out of 1,004 stocks

Pharmaceutical Preparations Industry

350th out of 489 stocks


KURA stock logo

About Kura Oncology (NASDAQ:KURA) Stock

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Receive KURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter.

KURA Stock News Headlines

SVB Securities Sticks to Its Buy Rating for Kura Oncology (KURA)
Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
Brokerages Set Kura Oncology, Inc. (NASDAQ:KURA) PT at $31.50
Geron (GERN) Gets a Buy from Wedbush
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Q4 2022 Kura Oncology Inc Earnings Call
Kura Oncology's Earnings Outlook
Kura Wins FDA Clearance for Tumor Treatment
H.C. Wainwright Keeps Their Buy Rating on Kura Oncology (KURA)
Cramer Is Holding This Biotech Stock
See More Headlines
Receive KURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter.

KURA Company Calendar

Last Earnings
2/23/2023
Today
4/01/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KURA
Fax
N/A
Employees
121
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$31.20
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+155.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-135,840,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.28 per share

Miscellaneous

Free Float
64,743,000
Market Cap
$837.02 million
Optionable
Optionable
Beta
0.93

Key Executives

  • Troy E. Wilson
    Chairman, President, CEO & Chief Financial Officer
  • Kathleen Ford
    Chief Operating Officer
  • Stephen Dale
    Chief Medical Officer
  • Mollie Leoni
    Senior Vice President-Clinical Development
  • Thomas Doyle
    Chief Accounting Officer & Senior VP-Finance













KURA Stock - Frequently Asked Questions

Should I buy or sell Kura Oncology stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KURA shares.
View KURA analyst ratings
or view top-rated stocks.

What is Kura Oncology's stock price forecast for 2023?

5 brokers have issued 12 month price targets for Kura Oncology's stock. Their KURA share price forecasts range from $25.00 to $40.00. On average, they predict the company's share price to reach $31.20 in the next year. This suggests a possible upside of 155.1% from the stock's current price.
View analysts price targets for KURA
or view top-rated stocks among Wall Street analysts.

How have KURA shares performed in 2023?

Kura Oncology's stock was trading at $12.41 at the beginning of 2023. Since then, KURA stock has decreased by 1.5% and is now trading at $12.23.
View the best growth stocks for 2023 here
.

When is Kura Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our KURA earnings forecast
.

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) announced its quarterly earnings results on Thursday, February, 23rd. The company reported ($0.49) EPS for the quarter, beating analysts' consensus estimates of ($0.58) by $0.09.

What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

How do I buy shares of Kura Oncology?

Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kura Oncology's stock price today?

One share of KURA stock can currently be purchased for approximately $12.23.

How much money does Kura Oncology make?

Kura Oncology (NASDAQ:KURA) has a market capitalization of $837.02 million. The company earns $-135,840,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis.

How many employees does Kura Oncology have?

The company employs 121 workers across the globe.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The official website for the company is www.kuraoncology.com. The company can be reached via phone at (858) 500-8800 or via email at ir@kuraoncology.com.

This page (NASDAQ:KURA) was last updated on 4/1/2023 by MarketBeat.com Staff